These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 4807057)

  • 21. Involvement of enhanced coagulation and fibrinolysis system in induction of atherosclerosis in hyperlipidemic rabbits fed on a high cholesterol diet.
    Ichino K; Okazaki M; Usami S; Oguchi K
    In Vivo; 1997; 11(2):115-23. PubMed ID: 9179603
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proceedings: The plasminogen activator content of the arterial wall in different arteries.
    Donner L; Safránková D
    Thromb Diath Haemorrh; 1975 Nov; 34(2):608. PubMed ID: 1198533
    [No Abstract]   [Full Text] [Related]  

  • 23. Changes in vessel wall plasminogen activator activity and smooth muscle cell proliferation and activation after arterial injury.
    More RS; Underwood MJ; Brack MJ; de Bono DP; Gershlick AH
    Cardiovasc Res; 1995 Jan; 29(1):22-6. PubMed ID: 7895234
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fibrinolysis--a review.
    Kane KK
    Ann Clin Lab Sci; 1984; 14(6):443-9. PubMed ID: 6239587
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
    Guimarães AH; Rijken DC
    Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clot lysis activity of plasminogen activator isolated from human tissue].
    Matsuo O
    Rinsho Byori; 1982 Jun; Suppl 50():167-77. PubMed ID: 6890121
    [No Abstract]   [Full Text] [Related]  

  • 27. Staphylokinase reduces plasmin formation by endogenous plasminogen activators.
    Jin T; Bokarewa M; Zhu Y; Tarkowski A
    Eur J Haematol; 2008 Jul; 81(1):8-17. PubMed ID: 18331597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Local heat shock priming promotes recanalization of thromboembolized microvasculature by upregulation of plasminogen activators.
    Rücker M; Schäfer T; Scheuer C; Harder Y; Vollmar B; Menger MD
    Arterioscler Thromb Vasc Biol; 2006 Jul; 26(7):1632-9. PubMed ID: 16627801
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasminogen activator content in heart tissue and perfusate under various experimental conditions.
    Lyutova LV; Andreenko GV; Perova EV; Malchikova LS
    Cor Vasa; 1983; 25(3):206-12. PubMed ID: 6684535
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy.
    Collen D; Lijnen HR
    Thromb Haemost; 1995 Jul; 74(1):167-71. PubMed ID: 8578451
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
    Munkvad S
    Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulation of the procoagulant response to arterial injury.
    Taubman MB; Giesen PL; Schecter AD; Nemerson Y
    Thromb Haemost; 1999 Aug; 82(2):801-5. PubMed ID: 10605785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Studies of coagulation and fibrinolysis of the arterial and venous blood in normal subjects and patients with atherosclerosis.
    NAIMI S; GOLDSTEIN R; PROGER S
    Circulation; 1963 May; 27():904-18. PubMed ID: 13937272
    [No Abstract]   [Full Text] [Related]  

  • 34. [Fibrinolysis and humoral syndrome in atherosclerosis].
    RAYNAUD R; BROCHIER M; GRIGUER P
    Presse Med (1893); 1961 Nov; 69():2185-6. PubMed ID: 14490737
    [No Abstract]   [Full Text] [Related]  

  • 35. [Behavior of fibrinolytic activity of the plasma in various stages of atherosclerosis].
    SZCZEKLIK E; JANIAKOWA A; POTOCZEK S
    Pol Arch Med Wewn; 1960; 30():969-72. PubMed ID: 13774505
    [No Abstract]   [Full Text] [Related]  

  • 36. [Mechanisms activating and inhibiting the fibrinolysis system].
    Dmoszyńska-Giannopoulou A
    Przegl Lek; 1987; 44(5):440-2. PubMed ID: 3310126
    [No Abstract]   [Full Text] [Related]  

  • 37. The spectrum of plasminogen activator-dependent fibrinolysis-altered psychoinduced vasopermeability syndrome.
    Panconesi E; Hautmann G
    Clin Dermatol; 1999; 17(5):609-13. PubMed ID: 10590858
    [No Abstract]   [Full Text] [Related]  

  • 38. [Spontaneous fluctuations in fibrinolysis].
    Shershevskiĭ MG
    Lab Delo; 1966; 5():274-6. PubMed ID: 4168948
    [No Abstract]   [Full Text] [Related]  

  • 39. Possible effects of risk factors on fibrinolysis.
    Kwaan HC
    Adv Exp Med Biol; 1978; 104():295-300. PubMed ID: 717138
    [No Abstract]   [Full Text] [Related]  

  • 40. [TREATMENT WITH SEX HORMONES AND FIBRINOLYSIS IN ATHEROSCLEROSIS].
    SHERSHEVSKII MG
    Ter Arkh; 1964 Sep; 36():10-3. PubMed ID: 14258760
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.